Therapeutic area
Hematology and blood cancers
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
31
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
285
Industry-sponsored
Recruiting Phase 3
154
Industry-sponsored
Recruiting Phase 4 (post-approval)
19
Industry-sponsored
Recent approvals
- Mimrylo (Rusfertide Acetate) · Takeda Pharms Am NovelPriority reviewOrphanAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers Squibb NovelPriority reviewOrphanAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLC OrphanJul 9, 2026
- Beqalzi (Sonrotoclax) · Beone Medicines USA NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 13, 2026
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Tecvayli (Teclistamab-Cqyv) · Janssen Biotech Breakthrough therapyPriority reviewOrphanMar 5, 2026
- Epkinly (Epcoritamab-Bysp) · Genmab US, Inc. Breakthrough therapyPriority reviewOrphanNov 18, 2025
- Komzifti (Ziftomenib) · Kura NovelBreakthrough therapyPriority reviewOrphanNov 13, 2025
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
- Gazyva (Obinutuzumab) · Genentech Breakthrough therapyOct 17, 2025
- Wayrilz (Rilzabrutinib) · Genzyme Corp NovelOrphanAug 29, 2025
To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids
- Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc. NovelAccelerated approvalPriority reviewOrphanJul 2, 2025
To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody
- Uplizna (Inebilizumab-Cdon) · Viela Bio Breakthrough therapyPriority reviewOrphanApr 3, 2025
- Qfitlia (Fitusiran Sodium) · Genzyme Corp NovelOrphanMar 28, 2025
To prevent or reduce the frequency of bleeding episodes in hemophilia A or B
- Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025
For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
- Alhemo (Concizumab-Mtci) · Novo Nordisk INC NovelPriority reviewOrphanDec 20, 2024
For routine prophylaxis to prevent bleeding episodes in hemophilia A and B
- Revuforj (Revumenib Citrate) · Syndax NovelBreakthrough therapyPriority reviewOrphanNov 15, 2024
To treat relapsed or refractory acute leukemia
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- OrelabrutinibICP-022Phase 311 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Largest recruiting Phase 3 trials
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05552222 · 1,590 participants (planned) · Start Oct 25, 2022 · Primary completion Apr 30, 2031
Drug: Teclistamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Tucson, Arizona; Clovis, California · 270 sites in all
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPivotal-lookingRecruiting
Kura Oncology, Inc.Industry
NCT07007312 · 1,300 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 2031
Drug: Ziftomenib; Placebo and 4 more · For: Acute Myeloid Leukemia (AML)
Sites: Gilbert, Arizona; Clovis, California; La Jolla, California · 141 sites in all
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136559 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Sep 7, 2032
Drug: Nemtabrutinib; Ibrutinib and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 206 sites in all
PfizerPfizer (PFE)
NCT05623020 · 1,060 participants (planned) · Start Nov 10, 2022 · Primary completion Oct 18, 2030
Drug: Elranatamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Daphne, Alabama; Fairhope, Alabama; Mobile, Alabama · 180 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06717347 · 1,046 participants (planned) · Start Jan 27, 2025 · Primary completion Jul 2, 2029
Drug: Zilovertamab vedotin; Rituximab and 8 more · For: Diffuse Large B-Cell Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 289 sites in all
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06549595 · 1,018 participants (planned) · Start Aug 7, 2024 · Primary completion Nov 26, 2031
Drug: Surovatamig; R-CHOP and 2 more · For: Untreated Follicular Lymphoma
Sites: Huntsville, Alabama; Anchorage, Alaska; Phoenix, Arizona · 244 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07665450 · 1,000 participants (planned) · Start Sep 9, 2026 · Primary completion Sep 4, 2030
Drug: Ramantamig; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Darlinghurst, Australia; South Brisbane, Australia; Brno, Czechia · 103 sites in all
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07634471 · 960 participants (planned) · Start Jun 22, 2026 · Primary completion Jul 23, 2032
Drug: MK-1045; Rituximab and 7 more · For: Follicular Lymphoma
Sites: Duarte, California; Lexington, Kentucky; Hackensack, New Jersey · 40 sites in all
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07222761 · 915 participants (planned) · Start Jan 2, 2026 · Primary completion May 21, 2029
Drug: Linvoseltamab; Carfilzomib and 4 more · For: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sites: Atlanta, Georgia; Ann Arbor, Michigan; New York, New York · 60 sites in all
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06091865 · 904 participants (planned) · Start Dec 13, 2023 · Primary completion Mar 30, 2028
Drug: Odronextamab; Rituximab and 4 more · For: Diffuse Large B-cell Lymphoma (DLBCL)
Sites: Scottsdale, Arizona; Los Angeles, California; Orange, California · 195 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.